DIA and MHRA announce speaker line-up for inaugural global summit

Senior leaders from some of the world’s foremost regulatory authorities, pharmaceutical companies, health technology organisations, academic institutions and patient groups will come together in London this November as the Medicines and Healthcare products Regulatory Agency (MHRA) and the Drug Information Association (DIA) host the inaugural DIA-MHRA Global Summit. 

Representatives from organisations including the US Food and Drug Administration (FDA), India’s Central Drugs Standard Control Organisation (CDSCO), Swissmedic, Australia’s Therapeutic Goods Administration (TGA), HM Government, Microsoft, GSK, AstraZeneca, IQVIA, BioNTech, NICE, HDRS, LifeArc and Duchenne UK will join discussions on how greater global collaboration can help accelerate safe, effective and innovative healthcare for patients. 

Held on 16 and 17 November 2026 alongside a significant programme of activity throughout London Life Sciences Week, the Summit will provide a unique international forum for regulators, industry leaders, academics, investors, technology innovators and patient representatives to explore how healthcare systems can work together to support innovation while maintaining public trust and patient safety. 

Under the theme “Global Collaboration for Safer and Smarter Health Innovation”, the programme will address some of the most significant opportunities and challenges facing healthcare today, including regulatory innovation, advanced therapies, artificial intelligence, health data, patient access, rare diseases, investment in life sciences and international regulatory cooperation. 

The programme features leading voices from across the life sciences ecosystem, reflecting the breadth of expertise needed to shape the future of health innovation.